Skip to main content
. 2014 Jan 23;9(1):e85881. doi: 10.1371/journal.pone.0085881

Table 2. Level of strength-of-evidence of HIV infection/AIDS in 171 cancer cases that were registered.

HIV Serology
Level Strength-of-Evidence Total(n = 171) Initial HIV(+) Serology (n = 25) Subsequent ConfirmedHIV(+) Serology (n = 22) Total HIV(+)Serology Clinical CriteriaOnly (n = 24)
Any CD4+ lymphocyte countCD4+ count <350/µL 48 (28%)30 (18%) 7 (28%)2 (8%) 13 (37%)8 (36%) 20 (33%)10 (21%) 28 (23%)20 (16%)
Any antiretroviral (cARV) therapySpecific cARV regimenRegimen not specified 87 (51%)38 (22%)49 (29%) 12 (48%)3 (12%)9 (36%) 16 (73%)13 (59%)3 (14%) 28 (60%)16 (34%)12 (26%) 59 (48%)22 (18%)*37 (30%)
WHO clinical stage and/or ISSin medical record 171 (100%) 25 (100%) 22 (100%) 47 (100%) 124 (100%)

Of the subsequent confirmed HIV(+) serology 12 were identified at the Comprehensive Care Clinic and 10 at the Department of Radiation Oncology at Kenyatta National Hospital. [Notes: *Statistically significant difference (p = 0.022) between positive serology group (n = 47) and clinical criteria only group (n = 124) with respect to the level strength-of-evidence (Chi-square test)].

HHS Vulnerability Disclosure